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OBJECTIVES: Despite progress in the treatment of schizophre-
nia following the introduction of atypical antipsychotics in the
late 1990s, current pharmacological options still carry limita-
tions. Sertindole is an atypical antipsychotic with a good
tolerability proﬁle likely to favour long-term adherence, reduc-
tions in relapse and re-hospitalisation rates, and improvements
in overall functioning. METHODS: A Markov model was
developed to estimate the cost-effectiveness of sertindole com-
pared with haloperidol, risperidone, olanzapine and aripipra-
zole in the management of schizophrenia in Norway over a
ﬁve-year period. Patients entered the model upon experiencing
intolerance to their antipsychotic treatment during an episode
of acute psychopathology. Confounding factors included drug-
induced adverse events (extrapyramidal symptoms, weight gain,
sedation, sexual dysfunction, diabetes), compliance, relapse and
treatment setting. Effectiveness was deﬁned as the length of
time without relapse over the two-year evaluation period, and
by Quality Adjusted Life Years (QALYs). Parameter estimates
were based upon published literature and clinical trial data.
Resource use data were obtained through consultation with a
Norwegian psychiatric expert, and costs were evaluated from
the Norwegian societal perspective. RESULTS: The time
without relapse (over ﬁve-year) for patients receiving sertindole
was superior to those with haloperidol, risperidone, olanzapine
and aripiprazole (1.780 versus 1.661, 1.778, 1.773 and 1.770).
Per patient costs over 5-year with sertindole was below that of
haloperidol and aripiprazole (NOK 1.598k versus 1.688k and
1.604k) but above the costs of risperidone and olanzapine
(NOK 1.598 versus 1.571k and 1.573k). Based on the outcome
of the model the effectiveness rates for sertindole is equivalent
to that of the other atypical antipsychotics. Medical costs
(including in- and outpatient care) for sertindole are equivalent
to or marginally higher compared to the other atypical antip-
sychotics. CONCLUSIONS: With equivalent clinical beneﬁts, a
good tolerability proﬁle and similar costs, sertindole is an addi-
tional valuable treatment alternative to other atypical antipsy-
chotics available in Norway.
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OBJECTIVES: To evaluate the impact of including paliperidone
ER in the Brazilian Public Health Care System, using a health
economic evaluation in comparison to the novel atypical agents
that are included in the schizophrenia guidelines (olanzapine,
quetiapine, ziprasidone). METHODS: A decision tree model
was developed describing the clinical evolution of patients with
acute exacerbation of schizophrenia during a one year period.
Published medical literature, unpublished clinical trial, database
information and a clinical expert panel populated the model.
All unit costs represent costs for the public HC system (SUS).
Outcomes included percentage of patients discontinuing, days
without therapy, percentage, number and duration of relapses
and direct medical costs. RESULTS: Long-term effectiveness
(number of stable days) of paliperidone ER (280) was similar
to olanzapine (279) and better than ziprasidone (272) and
quetiapine (267). Paliperidone ER was the treatment arm
with lower annual costs per patient (US$2628), followed by
ziprasidone (US$2655), olanzapine (US$2899) and quetiapine
(US$3253), respectively. Almost half of the treatment cost is
due to hospitalization, followed by medication cost, day hos-
pital, mental health clinic, social/group therapy visit, physician
visit and emergency room visit. CONCLUSIONS: Due to its
well-balanced efﬁcacy-safety proﬁle, the long term effectiveness
of paliperidone ER matched that of olanzapine and is better
than ziprasidone and quetiapine over the one year period.
Moreover, paliperidone ER was also the alternative with the
lowest treatment and overall costs for the public health
system. As such, including paliperidone ER in the Brazilian
Public Health System has the potential to further improve out-
comes for patients with schizophrenia while reducing public
expenditures.
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OBJECTIVES: To evaluate 12 months cost-effectiveness of ris-
peridone long-acting injection (RLAI) in patients with schizo-
phrenia enrolled in the electronic-Schizophrenia Treatment
Adherence Registry (e-STAR) from Czech Republic.
METHODS: e-STAR is an international long-term, prospective,
observational study in patients with schizophrenia who com-
menced RLAI treatment (based on SmPC indication criteria).
Analyzed data covered one year of retrospective (prior to RLAI
initiation) and 12 months of prospective observation. A total of
156 patients have completed the 12 months prospective period.
Assessed costs were: hospitalisation (duration and frequency),
antipsychotic medication and co-medication all from the payer’s
perspective in 2007 prices. Efﬁcacy parameters included GAF
(Global Assessment of Functioning) and CGI-S (Clinical Global
Impression-Severity) scores. RESULTS: Mean annual costs per
patient increased form €2361 in the retrospective period to
€4695 during the prospective observation. Mean cost drivers
were hospitalisation (60.6 % of total medical retrospective
costs) and antipsychotic medication (89.2 % of total medical
prospective costs). Costs of RLAI could not be offset by signiﬁ-
cant reductions in hospitalization (both frequency and duration
per event) and co-medication. Improvements in GAF (47.6 vs.
71.1) and CGI (4.78 vs. 3.16) scores resulted in incremental
cost-effectiveness ratios of €960 to €1440 per improvement by 1
category of clinical signiﬁcance (1 point for CGI and 10 points
for GAF). CONCLUSIONS: Switching to risperidone long-
acting injection in patients with treatment failure, non-
compliance or intolerance of current antipsychotic medication is
cost-effective despite higher costs of antipsychotic medication.
The analyses yield incremental cost-effectiveness ratios fall
below commonly accepted willingness to pay thresholds.
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